GlassScriptPhysician profile
Bindu J Alexander
NPI 1639150220
$2,251.51
in general payments reported to CMS, 2019-2025
23 companies · $381 in 2025
The $381 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $537 · 2020: $483 · 2021: $294 · 2022: $139 · 2023: $357 · 2024: $59.85 · 2025: $381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $798.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $798.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $525.30 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $453.80 | 2019-2025 | Fasenra, Farxiga |
| Lilly USA, LLC | $201.51 | 2020-2024 | Zepbound |
| Abbvie INC. | $200.59 | 2019-2023 | Vraylar |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $181.60 | 2024-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.46 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $72.83 | 2019-2021 | |
| Allergan, INC. | $55.30 | 2019-2020 | |
| Dexcom, INC. | $55.23 | 2022-2023 | Dexcom G6 Transmitter |
| Abbott Laboratories | $53.85 | 2022-2023 | Freestyle Libre 3 |
| Alk-Abello, INC | $48.23 | 2019 | |
| Genentech USA, INC. | $42.08 | 2019-2021 | |
| Glaxosmithkline, LLC. | $40.10 | 2025 | Trelegy Ellipta |
| Phadia US INC. | $39.52 | 2022-2024 | Immunocap |
| Paratek Pharmaceuticals, INC. | $30.14 | 2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $27.54 | 2019-2020 | |
| Amgen INC. | $25.90 | 2021 | |
| Ars Pharmaceuticals Operations, INC. | $24.45 | 2025 | Neffy |
| Optinose US, INC. | $22.88 | 2021 | |
| Daiichi Sankyo INC. | $19.17 | 2023 | Injectafer |
| Exact Sciences Corporation | $18.37 | 2025 | Cologuard Collection Kit |
| Currax Pharmaceuticals LLC | $16.22 | 2023 | Contrave |
| Sanofi Pasteur INC. | $12.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bindu Alexander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.